Overall, the introduction of CA-62 or a panel (CA-62, CEA and CYFRA 21-1) screening into the health system prior to LDCT lung cancer screening can reduce the overall cost of LC screening programs by dropping the burden of LDCT and conducting additional testing for patients with suspicious tomograms. The gene discussed is CEACAM5; the disease is lung cancer.